Align Technology has delivered 3 consecutive quarterly earnings beats averaging roughly 10% above estimates and converts 125% of net income into free cash flow, but the stock is near its analyst consensus target with just 2% upside remaining and an unfavorable reward-to-risk ratio; elevated put-to-call activity and 80% product concentration in the clear aligner segment limit the near-term conviction case.
Thesis pillars
- Clear Aligner Product Concentration↑Improving
- Consecutive Earnings Beat Streak↑Improving
- Superior Free Cash Flow Conversion→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 27, 2026
Align Technology, Inc. (ALGN) Stock Analysis
Recovery setup
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $153.62, but acceptable to hold if already in. Reasons: Concentration risk — Product: Clear Aligner segment (80.0%); Thin upside margin: 7.0%.
Align Technology designs and manufactures Invisalign clear aligners (80% of 2025 worldwide net revenues) and iTero intraoral scanners plus exocad CAD/CAM software (the remaining 20%), sold globally to orthodontists, general dental practitioners, and dental laboratories. Over 22... Read more
Hold if already holding. Not a fresh buy at $153.62, but acceptable to hold if already in. Reasons: Concentration risk — Product: Clear Aligner segment (80.0%); Thin upside margin: 7.0%. Chart setup: Death cross but MACD improving, RSI 72. Maintain position. Not compelling to add more. Score 5.5/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Align Technology, Inc.
About Align Technology, Inc.
Align Technology's Invisalign clear aligner system — FDA-cleared in 1998 and used in more than 22 million patient treatments globally — generated approximately 80% of the company's 2025 worldwide net revenues, with iTero intraoral scanners and exocad CAD/CAM software contributing the remaining 20%. The company serves orthodontists, general dental practitioners, DSOs, and dental laboratories through regional headquarters in Raleigh, Rotkreuz (Switzerland), and Singapore, with over 95% of prescription orders now submitted via digital scan.
Align Technology generates revenue through tiered Invisalign treatment packages — from limited-stage packages for minor corrections to multi-stage packages addressing complex malocclusion cases — plus Vivera retainers, iTero scanner hardware, software subscriptions, and exocad CAD/CAM licenses. Orthodontists and GPs must complete Invisalign training before prescribing, which reinforces adoption and creates friction for switching to competing products. Products are sold directly through a dedicated salesforce to practitioners, DSOs, and dental labs, with agents and distributors handling certain international markets. Revenue is sensitive to consumer discretionary spending because orthodontic treatment competes with lower-cost wires and brackets and is often treated as an elective procedure; uncertain economic outlooks in the United States, China, and European markets have historically reduced demand. China volume-based procurement programs and geographic mix shifts toward lower-priced regions may weigh on average selling prices. The company faces growing competition from DTC clear aligner providers requiring little to no in-office care, white-label third-party manufacturers, and doctors or DSOs producing aligners in-house.
Show full overview
Align Technology estimates its Invisalign System captures about 10% of the approximately 22 million annual orthodontic case starts through orthodontists globally, suggesting substantial untapped share of the wires-and-brackets market. However, the 10-K acknowledges that a meaningful segment of dental professionals believes Invisalign treatment is appropriate for only a limited percentage of patients, constraining physician-side adoption. The company manufactures clear aligners in a facility in Mexico and ships them to the United States primarily for domestic customers, exposing production costs to potential Section 232 trade investigations into medical equipment and device imports.
See also: Healthcare · Medical Instruments & Supplies
From Align Technology, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-10-29Recent Developments — Align Technology, Inc.
Latest news
- NEWS Align Technology (ALGN) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance — Yahoo Finance neutral
- NEWS Align Technology (NASDAQ:ALGN) Reports Q2 CY2026 In Line With Expectations But Quarterly Revenue Guidance Slightly Misse — StockStory neutral
- NEWS Align Technology (ALGN) Q2 Earnings and Revenues Top Estimates - Yahoo Finance — Yahoo Finance positive
- NEWS Earnings Flash (ALGN) Align Technology, Inc. Posts Q2 Adjusted EPS $2.64 per Share, vs. FactSet Est of $2.62 - marketscr — marketscreener.com positive
- NEWS ALIGN TECHNOLOGY ($ALGN) Releases Q2 2026 Earnings - Quiver Quantitative — Quiver Quantitative positive
Generated 2026-10-29T11:53:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductClear Aligner segment80%10-K Item 1: 'For the year ended December 31, 2025, Clear Aligner net revenues represented approximately 80% of worldwide net revenues'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $153.62, but acceptable to hold if already in. Reasons: Concentration risk — Product: Clear Aligner segment (80.0%); Thin upside margin: 7.0%. Chart setup: Death cross but MACD improving, RSI 72. Maintain position. Not compelling to add more. Analyst target $164.31 (+7.0%), stop $145.66 (−5.5%), A.R:R 0.7:1. Score 5.5/10, moderate confidence.
Analyst target: $164.31 (+7.0% upside). Analyst target $164.31 (+7.0%), stop $145.66 (−5.5%), A.R:R 0.7:1. Stop-loss: $145.66.
Concentration risk — Product: Clear Aligner segment (80.0%); Thin upside margin: 7.0%; Weak growth.
Align Technology, Inc. trades at a P/E of 22.4 (forward 12.4). TrendMatrix value score: 7.5/10. Verdict: Hold.
23 analysts cover ALGN with a consensus score of 3.8/5. Average price target: $189.
What does Align Technology, Inc. do?Align Technology designs and manufactures Invisalign clear aligners (80% of 2025 worldwide net revenues) and iTero...
Align Technology designs and manufactures Invisalign clear aligners (80% of 2025 worldwide net revenues) and iTero intraoral scanners plus exocad CAD/CAM software (the remaining 20%), sold globally to orthodontists, general dental practitioners, and dental laboratories. Over 22 million patients have been treated with the Invisalign System since 1998 FDA clearance.